Vaccinology : (Record no. 44101)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 11050nam a22004933i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC1884289 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240729123239.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2015 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781118636282 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9780470656167 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC1884289 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL1884289 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaPaEBR)ebr10995111 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaONFJC)MIL674985 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)898103648 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RA638 -- .V33 2015eb |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Milligan, Gregg N. |
| 245 10 - TITLE STATEMENT | |
| Title | Vaccinology : |
| Remainder of title | An Essential Guide. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Newark : |
| Name of producer, publisher, distributor, manufacturer | John Wiley & Sons, Incorporated, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2015. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2015. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (403 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Cover -- Title page -- Copyright page -- Contents -- Contributors -- Preface -- 1: The history of vaccine development and the diseases vaccines prevent -- The 18th century: vaccines for smallpox -- The 19th century: new understanding of infectious diseases and immunity -- The 20th century: the control of diseases using vaccines -- Vaccines -- Vaccines developed by trial and error -- Vaccines prepared by trial and error attenuation -- Vaccines for polysaccharide encapsulated bacteria -- Vaccines for hepatitis viruses -- Vaccines for human papillomaviruses -- Influenza -- Influenza vaccines -- Inactivated influenza vaccines -- Live attenuated influenza vaccine -- Rotavirus vaccines -- Further reading -- 2: The vaccine development pathway -- Introduction -- Regulation and approval of vaccines -- Basic research and development -- Manufacturing and process development -- Investigational New Drug Application: the "IND" -- Clinical trials -- The biologics license application -- Meetings with regulatory agencies -- Post-licensure activities -- Alternative pathways to licensure -- Further reading -- 3: Control and eradication of human and animal diseases by vaccination -- The control of diseases by vaccination -- Herd immunity -- Smallpox -- Rinderpest -- Poliomyelitis -- Measles -- Foot-and-mouth disease -- Other potentially eradicable diseases -- Further reading -- 4: Pathogenesis of infectious diseases and mechanisms of immunity -- Introduction -- Definitions: colonization, infection, disease, signs, symptoms -- Transmission and portal of entry -- Routes of spread in the body -- Target organs and cells -- Mechanisms of tissue injury and disease -- Pathogen evasion of host defenses -- Vaccines for infectious diseases and mechanisms of vaccine-induced immunity -- Toxin-mediated diseases -- Tetanus -- Diphtheria -- Anthrax. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Diseases for which killed pathogen vaccines were developed -- Rabies -- Respiratory syncytial virus -- Epidemic louse-borne typhus -- Live attenuated pathogen vaccines -- Epidemic louse-borne typhus -- Yellow fever -- Childhood viral infections -- Subunit vaccines -- Hepatitis B -- Neisseria meningitidis -- Streptococcus pneumoniae -- Further reading -- 5: The host immune response, protective immunity, and correlates of protection -- Introduction -- Induction of innate immunity -- Toll-like receptors -- RIG-I-like receptors -- NOD-like receptors (NLRs) -- C-type lectin receptors -- Bridging innate and adaptive immunity -- Development of adaptive immune responses -- T lymphocyte immunity -- B lymphocyte immunity -- T cell-dependent B-cell responses -- Persistent production of vaccine-specific antibody and B-cell memory -- T cell-independent B-cell responses -- Mechanisms of antibody-mediated protection -- Development of immunity at mucosal sites -- Correlates of protection -- Benefits of identifying a vaccine correlate of protection -- Mechanisms of vaccine-induced protection -- Exotoxin-producing bacteria -- Yellow fever virus -- Variola (Smallpox) -- Varicella zoster virus (chickenpox/zoster) -- Rotavirus -- Further Reading -- 6: Adjuvants: making vaccines immunogenic -- What is an adjuvant and why are they added to certain vaccines? -- Characteristics of a good adjuvant -- Safety -- Types of vaccine adjuvants -- Antigen delivery vehicles -- Immunostimulatory adjuvants -- Combination adjuvants -- Adjuvants for veterinary vaccines -- Future challenges -- Further reading -- 7: Discovery and the basic science phase of vaccine development -- Basic science and translational research -- Mechanisms of disease and comparative pathogenesis -- Multi-segment viruses -- Overlapping areas of research -- Molecular biology and recombinant vaccines. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Therapeutic vaccines and vaccines against noninfectious agents -- Immunology of protection and adjuvants -- High-throughput methods and systems biology -- Bioinformatics and reverse vaccinology -- Additional roles for basic science in vaccine development -- Iterative cycle of vaccine development -- Vaccine delivery -- Toward personalized vaccinology -- Conclusions -- Further reading -- 8: Microbial-based and material-based vaccine delivery systems -- Virus vectors as vaccine platforms -- DNA viruses -- Poxviruses -- Adenovirus -- Adeno-associated viruses -- RNA viruses -- Alphavirus vectors -- Newcastle disease virus (NDV) -- Measles virus -- Vesicular stomatitis virus and rabies virus -- Flaviviruses -- Lentiviruses -- Other vaccine vectors -- Bacterial vectors as vaccine platforms -- Bacterial cell surface display systems -- Gram-negative display systems -- Gram-positive display systems -- Novel tuberculosis vaccines -- Novel delivery systems -- Bacterial ghost system -- Genetic vaccination -- Plant vectors -- MucoRice -- Biomaterials: a new generation of vaccine adjuvants and vaccine platforms -- Strategies for antigen encapsulation and presentation -- Strategies for antigen delivery -- Nanogels -- Strategies for activating innate immunity -- Conclusions and future directions for biomaterials -- Further reading -- 9: Licensed vaccines for humans -- Introduction -- Immunization strategies -- Immunization -- Passive immunization -- Active immunization -- Maternal immunization -- Cocooning (maternal and family/household vaccination) -- Ring immunization -- Booster immunizations -- Cell culture used to prepare vaccines -- Vaccine excipients -- Hypersensitivity -- Route of administration -- Dosing regimen -- Mucosal-based vaccines -- Specific vaccine types -- Live attenuated vaccines -- Inactivated vaccines -- Bacterial subunit vaccines. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Viral subunit vaccines -- DNA vaccines -- Vaccines for special populations -- Other considerations -- Further reading -- 10: Veterinary vaccines -- Vaccine selection for companion and food-producing animals -- Status of veterinary vaccines for infectious and noninfectious diseases in companion and food-producing animals -- Viruses -- Live attenuated virus vaccines -- Inactivated or killed virus vaccines -- Bacteria -- Parasites -- Fungi -- Status of vaccines for aquaculture -- Future challenges -- Further reading -- 11: Development of vaccines for microbial diseases -- Introduction -- Principles of vaccine design -- Product development pathway -- Upstream processes -- Downstream processes -- Examples of vaccine development and production -- Recombinant protein (hepatitis B) -- Bacterial polysaccharide (Streptococcus pneumoniae) -- Inactivated virus subunits (influenza) -- Inactivated virus (polio) -- Live attenuated (measles) -- Inactivated virus vaccine development (yellow fever) -- Animal models -- Nonclinical vaccine immunogenicity and efficacy -- Nonclinical vaccine safety and toxicity -- Good laboratory practices -- Further reading -- 12: The regulatory path to vaccine licensure -- Introduction -- Regulation of biologics -- The biological IND -- Content and format of the IND -- The US FDA CBER IND review process -- CBER organization structure -- The CBER review process for INDs -- The IND and 30-day review clock -- Alternate licensure strategies -- The "Animal Rule" -- Accelerated approval and priority review -- Environmental risk assessment -- Scope -- New Drug Application and Common Technical Document -- Common Technical Document -- Electronic submissions -- Submission and review of the NDA -- Maintenance of the NDA -- Worldwide regulatory authorities -- European Medicines Agency (EMA) -- Japan's Ministry of Health, Labor and Welfare. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | China Food and Drug Administration -- Australia's Therapeutic Goods Administration -- Health Canada -- Further reading -- 13: Veterinary vaccines: regulations and impact on emerging infectious diseases -- Global veterinary vaccine market -- Veterinary versus human vaccine development -- Veterinary vaccine regulations: an overview -- Veterinary vaccine regulations: USA, European Union, and Australia -- United States of America -- European Union (EU) -- Animal testing during vaccine development -- Impact of veterinary vaccines in public health -- Response of national authorities to animal disease threats -- Future challenges -- Further reading -- 14: Vaccine manufacturing -- Introduction -- Manufacturing principles -- Manufacturing steps -- Manufacturing definitions -- Examples of cell substrates -- Vaccine manufacturing: overview -- Examples of vaccine production -- Analytical aspects -- Good manufacturing practices -- Good manufacturing practices -- Good cell culture practices -- Good distribution and supply practices -- Future outlook -- New technologies -- Vaccine safety -- Mucosal vaccination -- Elimination of preservatives -- Influenza viral drift -- Further reading -- 15: Clinical evaluation of vaccines -- Introduction -- Phases of clinical trials -- Phase I -- Phase II -- Phase III -- Phase IV -- Government jurisdiction -- The investigational new drug process -- Good clinical practice (GCP) -- The sponsor -- The investigator -- Institutional review boards and independent ethics committees -- Conclusion -- Further reading -- 16: Vaccine recommendations and special populations -- What happens after a vaccine is licensed? -- Recommendations -- Mandates -- What are vaccination schedules? -- Are there any exceptions for certain people (special populations)? -- Children -- Adults -- Aging adult population -- Pregnant women -- Newborns. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Altered immunocompetence. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Vaccines - therapeutic use. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Barrett, Alan D. T. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Milligan, Gregg N. |
| Title | Vaccinology |
| Place, publisher, and date of publication | Newark : John Wiley & Sons, Incorporated,c2015 |
| International Standard Book Number | 9780470656167 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=1884289">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=1884289</a> |
| Public note | Click to View |
No items available.